Loading…
← CockpitCompetitor Analysis › ZYDUSLIFE.NS Zydus LifesciencesOpen in the cockpit ↗

Zydus LifesciencesZYDUSLIFE.NSCompetitor analysis, valuation and peers

India · INR·Pharma & Healthcare›Pharmaceuticals: Major

Indian pharmaceutical company making generic drugs, branded formulations and vaccines, with a significant US generics business.

≈ India's smaller Teva PharmaceuticalMomentum strong 78
Mkt cap
$12.8B
US dollars, full cap
Free float
24%
of shares outstanding
$/day
$21.2M
20-day average traded
Fwd P/E
30.0×
forward earnings
ROIC−WACC
-2.0 pp
WACC 11.3%
Hurdle
n/a
no reverse DCF
Next earnings
88 days
14 Feb 2027
Close · INR₹1,202
1D-0.2%
1W+0.2%
1M+7.9%
3M+7.7%
6M+18.0%
YTD+31.5%
1Y+26.3%
ATR %2.5%
Beta0.57
52w lowhigh5.1% off high

What Zydus Lifesciences does

Indian pharmaceutical company making generic drugs, branded formulations and vaccines, with a significant US generics business.

Earns from US generic drugs, sold mainly to wholesalers and pharmacy chains at competitive prices, and from branded medicines that Indian doctors prescribe. The US is its largest single market. The Patel family, with Chairman Pankaj Patel, is the promoter and controlling shareholder.

In one line: India's smaller Teva Pharmaceutical.

Products and services

  • US generic drugs
  • Branded formulations (India)
  • Vaccines/biosimilars

Customers

  • US pharmacy/distributor customers (generics)
  • Indian doctors/hospitals (branded formulations)

Where it sits in the supply chain

  • Healthcare
  • Pharmaceuticals
  • Generics & formulations - India/US

What could go right

  • US generic drug launches/market share gains
  • India branded formulations growth

What could go wrong

  • US generic drug price erosion
  • FDA regulatory/plant compliance risk

Moat: narrow (regulatory licence, scale, process know-how). FDA-approved manufacturing facilities and a broad generics pipeline built over decades of regulatory filings.

Headquarters: Ahmedabad, India · Founded: 1952 · Employees: 36,827

Named competitors

Zydus Lifesciences at a glance

Size Zydus Lifesciences (ZYDUSLIFE.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $12.8B, the 90th largest of 1,066 India companies the cockpit tracks. Shares closed at ₹1,202 on 18 Nov 2026.

Performance Over six months the shares gained 18.0%, against +8.3% for the median peer and +3.8% for the India market (cap-weighted) — 9th highest of 21 in its peer set.

Growth Revenue grew 24.0% over the last twelve months (peer median +14.5%); the operating margin is 17.0% (peer median 21.5%).

Valuation It trades at 30.0× forward earnings against a peer median of 26.6× (9th most expensive of 19).

Capital Return on invested capital runs 2.0 points below its cost of capital (11.3% WACC).

Next results Next results expected around 14 Feb 2027 (exchange calendar; dates can move).

Relative performance

10011012021 May 202621 Aug 202618 Nov 2026ZYDUSLIFE.NS 115Peer median 109
Six months, rebased to 100: Zydus Lifesciences against the median of its 20 peers (local-currency closes).

Zydus Lifesciences financials

Reported figures in INR; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue₹304B₹270B₹229B₹193B₹171B
Revenue growth—+18%+19%+13%—
Gross profit₹150B₹134B₹114B₹86.3B₹68.0B
EBITDA₹71.9B₹71.9B₹65.8B₹50.7B₹34.1B
Net income₹41.8B₹50.4B₹45.3B₹38.6B₹19.6B
Free cash flown/a-₹4.80B₹51.8B₹23.8B₹16.1B
Capital expendituren/a₹33.9B₹16.9B₹9.07B₹10.3B
Total debt₹140B₹125B₹32.2B₹8.04B₹11.9B

Quarterly statements and history in the cockpit →

Zydus Lifesciences competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+20%+40%+60%0%+10%6990DRREDDYLAURUSLABS1177REC600436MANKINDIPNRGEN6885060005386446ORNAVJAZZSOBITGTX300759EXELASNDSYREZYDUSLIFE.NS6-month return →1-month return →
Up and to the right = strong over both horizons. Zydus Lifesciences is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%0×500×1,000×6990DRREDDYLAURUSLABS1177REC6004366446ORNAVTGTXASNDZYDUSLIFE.NSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Zydus Lifesciences is the large dot.

Zydus Lifesciences competitors and peer comparison

Head to head with its named competitors (ZYDUSLIFE.NS vs TORNTPHARM.NS vs SUNPHARMA.NS vs CIPLA.NS)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Zydus Lifesciences ZYDUSLIFE.NS$12.8B+18%+24%17%30.0×n/a
Torrent Pharmaceuticals TORNTPHARM.NS$18.8B+3%+42%22%70.2×37.6%
Sun Pharmaceutical Industries SUNPHARMA.NS$48.0B-1%+12%23%36.0×28.7%
Cipla CIPLA.NS$12.2B+1%-1%13%29.1×28.4%

How Zydus Lifesciences compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Zydus Lifesciences against its 20 peers (data as of 18 Nov 2026)
MeasureZYDUSLIFE.NSPeer medianRank in peer set
1-month return+7.9%+6.1%9th highest of 21
6-month return+18.0%+8.3%9th highest of 21
Distance from 52-week high-5.1%-6.8%8th highest of 21
Revenue growth (TTM)+24.0%+14.5%6th highest of 20
Operating margin17.0%21.5%7th lowest of 20
Forward P/E30.0×26.6×9th most expensive of 19
ROIC minus cost of capital-2.0 pp+6.6 pp5th lowest of 20
EV / EBITDA18.2×19.5×8th cheapest of 15
Net debt / EBITDA1.2×-0.1×4th most indebted of 15

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Zydus Lifesciences ZYDUSLIFE.NSIndia$12.8B+18%+24%17%30.0×n/an/a
Sichuan Kelun-Biotech Biopharmaceutical 6990.HKHong Kong$13.0B-1%+44%-38%1,176.1×55.3%+33.6%
Dr. Reddy's Laboratories DRREDDY.NSIndia$12.5B+5%-4%9%32.0×30.7%+12.1%
Laurus Labs LAURUSLABS.NSIndia$13.4B+73%+23%24%76.4×51.2%+7.3%
Sbp 1177.HKHong Kong$12.2B+5%+15%30%17.5×-5.7%+5.4%
Recordati REC.MIItaly$12.0B+3%+8%30%16.6×1.1%+12.6%
Zhangzhou Pientzehuang Pharmaceutical 600436.SSChina$11.6B-4%-19%19%40.7×24.9%+6.8%
Mankind Pharma MANKIND.NSIndia$11.6B+5%+13%21%44.4×28.6%+18.1%
Ipsen IPN.PAFrance$14.8B+1%+14%30%10.8×-6.7%+7.2%
Repligen RGENUnited States$11.0B+55%+14%9%71.0×56.9%+15.0%
Sichuan Biokin Pharmaceutical 688506.SSChina$14.9B-7%+14%-43%n/an/an/a
Yunnan Baiyao 000538.SZChina$15.0B+11%+5%11%18.3×-0.2%+4.7%
PharmaEssentia 6446.TWTaiwan$15.0B+67%+78%40%31.9×23.7%+94.8%
Orion ORNAV.HEFinland$15.7B+41%+34%38%23.6×-6.2%+11.7%
Jazz Pharmaceuticals Public JAZZUnited States$15.9B+4%+13%25%9.3×-2.8%+12.5%
Swedish Orphan Biovitrum SOBI.STSweden$16.1B+6%+15%30%24.1×-2.1%+13.1%
TG Therapeutics TGTXUnited States$9.99B+66%+69%21%25.2×43.0%+426.7%
Pharmaron Beijing 300759.SZChina$9.90B+52%+18%14%36.8×n/an/a
Exelixis EXELUnited States$16.7B+37%+9%40%17.7×-3.8%+18.6%
Ascendis Pharma A/S ASNDUnited States$16.9B+12%+94%18%28.0×19.2%+152.4%
Spyre Therapeutics SYREUnited States$9.64B+41%n/an/an/an/an/a

Questions

Who are Zydus Lifesciences's main competitors?
Named competitors: Torrent Pharmaceuticals (TORNTPHARM.NS), Sun Pharmaceutical Industries (SUNPHARMA.NS), Cipla (CIPLA.NS). The cockpit's measured peer set (industry) also includes Sichuan Kelun-Biotech Biopharmaceutical (6990.HK), Dr. Reddy's Laboratories (DRREDDY.NS), Laurus Labs (LAURUSLABS.NS), Sbp (1177.HK), Recordati (REC.MI), Zhangzhou Pientzehuang Pharmaceutical (600436.SS).
Is Zydus Lifesciences expensive compared with its peers?
On forward p/e it trades at 30.0× against a peer median of 26.6×, 9th most expensive of 19 in its peer set.
How has Zydus Lifesciences stock performed?
Over six months to 18 Nov 2026 the shares returned +18.0% against +8.3% for the median peer; over one year +26.3%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.